サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1584105

クロストリジウム・ディフィシル感染症治療市場：製品タイプ別、投与経路別、流通経路別、国別、地域別 - 産業分析、市場規模、市場シェア、2024-2032年予測

Clostridioides Difficile Infection Treatment Market, By Product Type, By Route of Administration, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

出版日
ページ情報
英文 316 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
クロストリジウム・ディフィシル感染症治療市場：製品タイプ別、投与経路別、流通経路別、国別、地域別 - 産業分析、市場規模、市場シェア、2024-2032年予測
出版日: 2024年10月26日
発行: AnalystView Market Insights
ページ情報: 英文 316 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートハイライト

クロストリジウム・ディフィシル感染症治療市場規模は2023年に8億1,021万米ドルとなり、2024年から2032年にかけてCAGR 6.10％で拡大

クロストリジウム・ディフィシル感染症治療市場-市場力学

感染症の蔓延と新規治療法の開発が市場需要を促進

クロストリジウム・ディフィシル感染症治療市場は、感染症の有病率の上昇と新たな治療法の開発により、劇的な変化を遂げつつあります。クロストリジウム・ディフィシル感染症は、ヘルスケア環境や抗生物質の使用と関連することが多く、世界のヘルスケアシステムに大きな負担を与えており、先進的で効果的な治療オプションの必要性を浮き彫りにしています。市場力学にはいくつかの要因が影響しており、これらの感染症の発生率の増加はヘルスケアの大きな課題となっています。入院期間の長期化、広域抗生物質の普及、高齢化により、クロストリジウム・ディフィシル感染症に対する個人の感受性が高まっており、革新的で効果的な治療に対する需要が高まっています。技術の進歩は治療の展望を変えつつあり、抗菌剤、糞便微生物叢移植（FMT）、モノクローナル抗体などの新規治療がこれらの感染症に対抗する上で重要な役割を果たしています。さらに、患者固有の感染症プロファイルに基づく標的治療による精密医療の統合は、より個別化された効果的な治療戦略に寄与しています。

クロストリジウム・ディフィシル感染症治療市場-主要インサイト

当社のリサーチアナリストが共有した分析によると、世界市場は予測期間（2024-2032年）に約6.10%のCAGRで毎年成長すると予測されています。

投与経路別では、経口剤が2023年に最大市場シェアを示すと予測されました。

流通チャネル別では、2023年には病院薬局が主要タイプに

地域別では、北米が2023年に主要な収益源となった。

クロストリジウム・ディフィシル感染症治療市場-セグメンテーション分析：

世界のクロストリジウム・ディフィシル感染症治療市場は、製品タイプ、投与経路、流通チャネル、地域に基づいてセグメント化されます。

市場は投与経路に基づいて2つのカテゴリーに分けられる：経口剤と注射剤です。2023年においても、経口投与経路は患者にとって利便性が高くアクセスしやすいため、最も一般的です。メトロニダゾール、バンコマイシン、フィダキソマイシンなどの抗生物質の経口投与は、外来治療をサポートし、特に重症度の低い症例では患者のアドヒアランスを向上させる。しかし、重症例や複雑な症例では、抗生物質の注射製剤が利用されます。

市場は流通チャネルによって3つのカテゴリーに分けられる：病院薬局、小売薬局、通販薬局です。2023年には病院薬局が市場を独占すると予想されます。特に重症例では入院治療が必要であることから、病院薬局は重要な役割を果たしています。これらの感染症の一次治療センターとして、病院は治療薬の流通と投与の中心的役割を担っています。

クロストリジウム・ディフィシル感染症治療市場-地理的洞察

この市場は地理的な境界を超え、北米、ラテンアメリカ、欧州、アジア太平洋、中東・アフリカで存在感を示しています。北米は、2024年の市場シェアが大きく、市場関係者が新しい治療法を導入するための研究開発活動に注力していることから、予測期間中、クロストリジウム・ディフィシル感染症治療市場を独占すると予測されます。例えば、2022年9月、バイオテクノロジー企業であるSeres Therapeutics, Inc.は、クロストリジウム・ディフィシル感染症の再発予防を目的としたSER-109の米国食品医薬品局（FDA）への生物製剤承認申請（BLA）のローリング完了を発表しました。米国市場でのSER-109のイントロダクションは、この優位性に貢献すると予想されます。

クロストリジウム・ディフィシル感染症治療市場-競合情勢：

難治性クロストリジウム・ディフィシル感染症治療市場の各社は、自社のプレゼンスを確立・拡大するためにさまざまな戦略を練っています。特に標準的な抗生物質が無効な再発性CDIに対しては、革新的な治療法を生み出すための研究開発が重視されています。臨床試験を実施し、製品の有効性を実証するための実データを収集するためには、ヘルスケアプロバイダーや医療機関との協力が不可欠です。ヘルスケアは、最新の治療選択肢やガイドラインについて医療従事者を教育することに重点を置いています。さらに、企業はしばしば支払者と戦略的パートナーシップを結び、新しい治療法の償還を確保することで、規制上の課題に効果的に対処しながら患者アクセスを向上させています。

目次

第1章 クロストリジウム・ディフィシル感染症治療市場概要

  • 調査範囲
  • 市場推定年

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 クロストリジウム・ディフィシル感染症治療の主要市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 クロストリジウム・ディフィシル感染症治療産業研究

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しマッピング
  • 規制枠組み分析

第5章 クロストリジウム・ディフィシル感染症治療市場： COVID-19の影響分析

  • COVID-19以前の影響分析
  • COVID-19後の影響分析

第6章 クロストリジウム・ディフィシル感染症治療市場情勢

  • クロストリジウム・ディフィシル感染症治療市場シェア分析、2023年
  • 主要メーカー別内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 クロストリジウム・ディフィシル感染症治療市場-製品タイプ別

  • 概要
    • 製品タイプ別セグメントシェア分析
    • メトロニダゾール
    • バンコマイシン
    • フィダキソミシン

第8章 クロストリジウム・ディフィシル感染症治療市場- 投与経路別

  • 概要
    • 投与経路別セグメントシェア分析
    • 経口
    • 注射剤

第9章 クロストリジウム・ディフィシル感染症治療市場- 流通チャネル別

  • 概要
    • 流通チャネル別セグメントシェア分析
    • 病院薬局
    • 小売薬局
    • 通信販売薬局

第10章 クロストリジウム・ディフィシル感染症治療市場-地域

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋（APAC）
    • 概要
    • アジア太平洋地域の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東およびアフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第11章 主要ベンダー分析- クロストリジウム・ディフィシル感染症治療業界

  • 競合ダッシュボード
  • 企業プロファイル
    • Novartis
    • Mylan NV
    • Akorn
    • Teva Pharmaceutical Industries Ltd.
    • AstraZeneca
    • Apotex Inc.
    • AbbVie Inc.
    • Pfizer Inc.
    • Strides Pharma Science Limited
    • Sanofi
    • Ferring Pharmaceuticals
    • Sun Pharmaceutical Industries Ltd.
    • Merck &Co., Inc.
    • B. Braun Medical Inc.
    • Eli Lilly and Company
    • Actelion Pharmaceuticals Ltd.
    • Astellas Pharma
    • Perrigo Pharmaceutical.
    • Hikma Pharmaceutical PLC
    • Fresenius Kabi USA
    • Others

第12章 アナリストの全方位展望

目次
Product Code: ANV4055

REPORT HIGHLIGHT

Clostridioides Difficile Infection Treatment Market size was valued at USD 810.21 Million in 2023, expanding at a CAGR of 6.10% from 2024 to 2032.

Clostridioides difficile infection (CDI) is a serious gastrointestinal condition caused by the bacterium C. difficile, often triggered by antibiotic use that disrupts the normal gut microbiome. Treatment usually involves targeted antibiotics such as fidaxomicin or vancomycin. For recurrent infections, fecal microbiota transplantation (FMT) is an emerging option that restores healthy gut bacteria. The choice of treatment depends on the patient history, infection's severity, and the likelihood of recurrence. Prompt and appropriate management is important to prevent complications and minimize the risk of transmission in healthcare environments.

Clostridioides Difficile Infection Treatment Market- Market Dynamics

Increasing prevalence of infections and ongoing development of novel treatment methods to propel market demand

The Clostridium difficile infection treatment market is undergoing drastic transformation, driven by the rising prevalence of infections and ongoing development of novel treatment methods. Frequently associated with the healthcare settings and antibiotic use, Clostridium difficile infections pose a substantial burden on global healthcare systems, highlighting a need for an advanced and effective treatment options. Several factors influence market dynamics, with the increasing incidence of these infections being a major healthcare challenge. Prolonged hospital stays, widespread use of broad-spectrum antibiotics, and an aging population have heightened individual susceptibility to Clostridium difficile infections, creating a growing demand for innovative and effective treatments. Technological advancements are reshaping the treatment landscape, with novel therapies such as antimicrobial agents, fecal microbiota transplantation (FMT), and monoclonal antibodies playing a key role in combating these infections. Additionally, the integration of precision medicine, through targeted therapies based on a patient's specific infection profile, is contributing to more personalized and effective treatment strategies.

Clostridioides Difficile Infection Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 6.10% over the forecast period (2024-2032)

Based on Route of Administration segmentation, oral was predicted to show maximum market share in the year 2023

Based on Distribution Channel segmentation, Hospital Pharmacies was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Clostridioides Difficile Infection Treatment Market- Segmentation Analysis:

The Global Clostridioides Difficile Infection Treatment Market is segmented on the basis of Product Type, Route of Administration, Distribution Channel, and Region.

The market is divided into two categories based on Route of Administration: Oral and Injectables. In 2023, the oral route remains the most common due to its convenience and accessibility for patients. Oral administration of antibiotics, such as metronidazole, vancomycin, and fidaxomicin, supports outpatient care and improves patient adherence, particularly in less severe cases. However, in severe or complicated cases, injectable antibiotic formulations are utilized.

The market is divided into three categories based on Distribution Channel: Hospital Pharmacies, Retail Pharmacies and Mail-Order Pharmacies. Hospital pharmacies are expected to dominate the market in 2023. Hospital pharmacies play a key role, particularly given the need for inpatient care in severe cases. As primary treatment centers for these infections, hospitals are central to the distribution and administration of therapeutic agents.

Clostridioides Difficile Infection Treatment Market- Geographical Insights

This market transcends geographical boundaries, with a presence in North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. North America is projected to dominate the Clostridioides difficile infection treatment market during the forecast period, driven by the region's significant market share in 2024 and the focus of market players on research and development activities to introduce new therapies. For example, in September 2022, Seres Therapeutics, Inc., a biotechnology company, announced the completion of its rolling Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) for SER-109, aimed at preventing recurrent Clostridioides difficile infection. The introduction of SER-109 in the U.S. market is expected to contribute to this dominance.

Clostridioides Difficile Infection Treatment Market- Competitive Landscape:

Companies in the CDI treatment market devising various strategies to establish and expand their presence. A major emphasis is placed on research and development to create innovative therapies, especially for recurrent CDI, where standard antibiotics may be ineffective. Collaborations with healthcare providers and institutions are crucial for conducting clinical trials and gathering real-world data to demonstrate product efficacy. Marketing efforts focus on educating healthcare professionals about the latest treatment options and guidelines. Additionally, companies often form strategic partnerships with payers to secure reimbursement for new therapies, improving patient access while effectively addressing regulatory challenges.

Recent Developments:

In October 2022, Acurx Pharmaceuticals, Inc., a leading bioProduct Type company, made notable contributions to the field of infectious diseases by presenting both a poster and an oral presentation at the Infectious Disease Society of America (IDSA) IDWeek 2022 Conference.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CLOSTRIDIOIDES DIFFICILE INFECTION TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHT

Novartis

Mylan N.V.

Akorn

Teva Pharmaceutical Industries Ltd.

AstraZeneca

Apotex Inc.

AbbVie Inc.

Pfizer Inc.

Strides Pharma Science Limited

Sanofi

Ferring Pharmaceuticals

Sun Pharmaceutical Industries Ltd.

Merck & Co., Inc.

B. Braun Medical Inc.

Eli Lilly and Company

Actelion Pharmaceuticals Ltd.

Astellas Pharma

Perrigo Pharmaceutical.

Hikma Pharmaceutical PLC

Fresenius Kabi USA

Others

GLOBAL CLOSTRIDIOIDES DIFFICILE INFECTION TREATMENT MARKET, BY PRODUCT TYPE - MARKET ANALYSIS, 2019 - 2032

  • Metronidazole
  • Vancomycin
  • Fidaxomicin

GLOBAL CLOSTRIDIOIDES DIFFICILE INFECTION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Injectables

GLOBAL CLOSTRIDIOIDES DIFFICILE INFECTION TREATMENT MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Retail Pharmacies
  • Mail-Order Pharmacies

GLOBAL CLOSTRIDIOIDES DIFFICILE INFECTION TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Clostridioides Difficile Infection Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Clostridioides Difficile Infection Treatment Market Snippet by Product Type
    • 2.1.2. Clostridioides Difficile Infection Treatment Market Snippet by Route of Administration
    • 2.1.3. Clostridioides Difficile Infection Treatment Market Snippet by Distribution Channel
    • 2.1.4. Clostridioides Difficile Infection Treatment Market Snippet by Country
    • 2.1.5. Clostridioides Difficile Infection Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Clostridioides Difficile Infection Treatment Key Market Trends

  • 3.1. Clostridioides Difficile Infection Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Clostridioides Difficile Infection Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Clostridioides Difficile Infection Treatment Market Opportunities
  • 3.4. Clostridioides Difficile Infection Treatment Market Future Trends

4. Clostridioides Difficile Infection Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Clostridioides Difficile Infection Treatment Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Clostridioides Difficile Infection Treatment Market Landscape

  • 6.1. Clostridioides Difficile Infection Treatment Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Clostridioides Difficile Infection Treatment Market - By Product Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Product Type, 2023 & 2032 (%)
    • 7.1.2. Metronidazole
    • 7.1.3. Vancomycin
    • 7.1.4. Fidaxomicin

8. Clostridioides Difficile Infection Treatment Market - By Route of Administration

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 8.1.2. Oral
    • 8.1.3. Injectables

9. Clostridioides Difficile Infection Treatment Market - By Distribution Channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
    • 9.1.2. Hospital Pharmacies
    • 9.1.3. Retail Pharmacies
    • 9.1.4. Mail-Order Pharmacies

10. Clostridioides Difficile Infection Treatment Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Clostridioides Difficile Infection Treatment Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Clostridioides Difficile Infection Treatment Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Clostridioides Difficile Infection Treatment Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Clostridioides Difficile Infection Treatment Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Clostridioides Difficile Infection Treatment Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Clostridioides Difficile Infection Treatment Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Novartis
    • 11.2.2. Mylan N.V.
    • 11.2.3. Akorn
    • 11.2.4. Teva Pharmaceutical Industries Ltd.
    • 11.2.5. AstraZeneca
    • 11.2.6. Apotex Inc.
    • 11.2.7. AbbVie Inc.
    • 11.2.8. Pfizer Inc.
    • 11.2.9. Strides Pharma Science Limited
    • 11.2.10. Sanofi
    • 11.2.11. Ferring Pharmaceuticals
    • 11.2.12. Sun Pharmaceutical Industries Ltd.
    • 11.2.13. Merck & Co., Inc.
    • 11.2.14. B. Braun Medical Inc.
    • 11.2.15. Eli Lilly and Company
    • 11.2.16. Actelion Pharmaceuticals Ltd.
    • 11.2.17. Astellas Pharma
    • 11.2.18. Perrigo Pharmaceutical.
    • 11.2.19. Hikma Pharmaceutical PLC
    • 11.2.20. Fresenius Kabi USA
    • 11.2.21. Others

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us